GT-1/GT-055
/ Geom Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 16, 2021
In vitro and in vivo activity of GT-1, a novel siderophore cephalosporin, and GT-055, a broad-spectrum β-lactamase inhibitor, against biothreat and ESKAPE pathogens.
(PubMed, J Antibiot (Tokyo))
- "Here, we demonstrated sub-4 µg ml efficacy against a number of pathogens in vitro. We further determined that in mice infected via aerosol route with Yersinia pestis, efficacy of GT-1/GT-055 treatment is at least equivalent to the comparator antibiotic, ciprofloxacin."
Journal • Preclinical • Infectious Disease
May 24, 2020
In Vitro Activity of a Novel Siderophore-Cephalosporin, GT-1 and Serine-Type β-Lactamase Inhibitor, GT-055, against Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. Panel Strains.
(PubMed, Antibiotics (Basel))
- "This study investigates GT-1 (also known as LCB10-0200), a novel-siderophore cephalosporin, inhibited multidrug-resistant (MDR) Gram-negative pathogen, via a Trojan horse strategy exploiting iron-uptake systems...Compared with CAZ-AVI, GT-1/GT-055 exhibited lower MICs against E. coli and K. pneumoniae isolates. GT-1 demonstrated potent in vitro activity against clinical panel strains of E. coli, K. pneumoniae and Acinetobacter spp. GT-055 enhanced the in vitro activity of GT-1 against many GT-1-resistant strains."
Journal • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases
1 to 2
Of
2
Go to page
1